ATP7A and colorectal cancer: At present, studies have reported that elesclomol inhibits colorectal cancer by targeting ATP7A to manipulate cuproptosis and ferroptosis and have suggested elesclomol as a potential therapeutic agent for colorectal cancer [106], which is the best example of finding common ground for treatment by understanding the specific mechanisms of cells.